Literature DB >> 16126335

An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines.

Kuei-Tien Chen1, Jen-Der Lin, Miaw-Jene Liou, Hsiao-Fen Weng, C Allen Chang, Err-Cheng Chan.   

Abstract

Platelet-derived growth factor receptor (PDGFR) can bind to its ligand and consequently possess a kinase activity, and which is associated with the carcinogenesis of different cell types, including astrocytomas, oligodendrogliomas, and glioblastoma. In a cDNA microarray analysis, we observe the over-expressed mRNA of both PDGF-A and PDGF-alpha receptor in thyroid carcinoma cells. And the elevated protein expressions of PDGF-A and PDGF-alpha receptor in thyroid carcinoma cells were also confirmed by a Western blot analysis. The phosphorylation of PDGF-alpha receptor evaluated by an antibody against Tyr 720-phosphate was found in thyroid carcinoma cells. The tyrosine kinase activity of PDGF-alpha receptor was inhibited by tyrphostin AG1295 and showed a dose-dependent inhibition for the proliferation of thyroid carcinoma cells. These findings imply that autocrine activation of PDGF-alpha receptor plays a crucial role in the carcinogenesis of thyroid cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126335     DOI: 10.1016/j.canlet.2005.01.039

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.

Authors:  Enis Kostallari; Petra Hirsova; Alena Prasnicka; Vikas K Verma; Usman Yaqoob; Nicha Wongjarupong; Lewis R Roberts; Vijay H Shah
Journal:  Hepatology       Date:  2018-05-10       Impact factor: 17.425

2.  PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration.

Authors:  Huan-Yong Che; Hang-Yuan Guo; Xu-Wei Si; Qiao-Ying You; Wei-Ying Lou
Journal:  Tumour Biol       Date:  2014-05-28

3.  Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence?

Authors:  Patrizia Malkomes; Elsie Oppermann; Wolf-Otto Bechstein; Katharina Holzer
Journal:  Langenbecks Arch Surg       Date:  2011-05-08       Impact factor: 3.445

4.  Thyroid cancer: emerging role for targeted therapies.

Authors:  Jennifer A Sipos; Manisha H Shah
Journal:  Ther Adv Med Oncol       Date:  2010-01       Impact factor: 8.168

5.  Glioblastoma multiforme and papillary thyroid carcinoma - A rare combination of multiple primary malignancies.

Authors:  Swaroopa Pulivarthi; Elizabeth Haglind; Carl T McGary; Murali Krishna Gurram
Journal:  J Neurosci Rural Pract       Date:  2015 Apr-Jun

6.  Genome-wide expression analysis suggests a crucial role of dysregulation of matrix metalloproteinases pathway in undifferentiated thyroid carcinoma.

Authors:  Jesús Espinal-Enríquez; Said Muñoz-Montero; Ivan Imaz-Rosshandler; Aldo Huerta-Verde; Carmen Mejía; Enrique Hernández-Lemus
Journal:  BMC Genomics       Date:  2015-03-18       Impact factor: 3.969

Review 7.  Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Authors:  Ricardo Costa; Benedito A Carneiro; Sunandana Chandra; Sachin G Pai; Young Kwang Chae; Jason B Kaplan; Hannah B Garrett; Mark Agulnik; Peter A Kopp; Francis J Giles
Journal:  Drug Des Devel Ther       Date:  2016-02-29       Impact factor: 4.162

8.  Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Authors:  Ove Bruland; Øystein Fluge; Lars A Akslen; Hans G Eiken; Johan R Lillehaug; Jan E Varhaug; Per M Knappskog
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

9.  Macropinocytosis of the PDGF β-receptor promotes fibroblast transformation by H-RasG12V.

Authors:  C Schmees; R Villaseñor; W Zheng; H Ma; M Zerial; C-H Heldin; C Hellberg
Journal:  Mol Biol Cell       Date:  2012-05-09       Impact factor: 4.138

10.  Additive effect by combination of Akt inhibitor, MK-2206, and PDGFR inhibitor, tyrphostin AG 1296, in suppressing anaplastic thyroid carcinoma cell viability and motility.

Authors:  Huan-Yong Che; Hang-Yuan Guo; Xu-Wei Si; Qiao-Ying You; Wei-Ying Lou
Journal:  Onco Targets Ther       Date:  2014-03-14       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.